By Canadian Press

Health Canada reviewing AstraZeneca antibody drug to prevent symptomatic COVID-19

Nov 3, 2021 | 9:05 AM

OTTAWA — AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.

If approved, it would be the first antibody protection of its kind in Canada.

The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.

AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine. 

The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.

Meaningful Mementos

Remembering Someone You've Lost at Christmas

Dec 03, 2024

Seasonal Sorrow

How Do You Get Through The Holidays When You're Grieving?

Nov 01, 2024

Upcoming Events at Oliver's

Grief & Loss and Estate Planning Seminars

Oct 02, 2024

Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.

This report by The Canadian Press was first published Nov. 3, 2021.

The Canadian Press